These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 30811805)

  • 1. Twitter response to the 2018 US Preventive Services Task Force guidelines on prostate cancer screening.
    Ke Y; Taylor J; Gao L; Wang H; Zhao H; Byrne N; Modgil V; Butaney M; Makarov DV; Prabhu V; Loeb S
    BJU Int; 2019 Sep; 124(3):363-364. PubMed ID: 30811805
    [No Abstract]   [Full Text] [Related]  

  • 2. Re: National Prostate Cancer Screening Rates after the 2012 US Preventive Services Task Force Recommendation Discouraging Prostate-Specific Antigen-Based Screening.
    Penson DF
    J Urol; 2016 Apr; 195(4 Pt 1):928-9. PubMed ID: 27302784
    [No Abstract]   [Full Text] [Related]  

  • 3. Prostate-Specific Antigen Screening After 2012 US Preventive Services Task Force Recommendations.
    Sammon JD; Abdollah F; Choueiri TK; Kantoff PW; Nguyen PL; Menon M; Trinh QD
    JAMA; 2015 Nov; 314(19):2077-9. PubMed ID: 26575066
    [No Abstract]   [Full Text] [Related]  

  • 4. 2008 US Preventive Services Task Force recommendations and prostate cancer screening rates.
    Prasad SM; Drazer MW; Huo D; Hu JC; Eggener SE
    JAMA; 2012 Apr; 307(16):1692-4. PubMed ID: 22535850
    [No Abstract]   [Full Text] [Related]  

  • 5. Re: Changes in Prostate-specific Antigen Testing Relative to the Revised US Preventive Services Task Force Recommendation on Prostate Cancer Screening.
    Fleshner K; Carlsson SV
    Eur Urol; 2022 Mar; 81(3):313. PubMed ID: 35027257
    [No Abstract]   [Full Text] [Related]  

  • 6. Re: Prostate Cancer Incidence 5 Years After US Preventive Services Task Force Recommendations Against Screening.
    Lehrer S; Rheinstein PH
    J Natl Cancer Inst; 2020 Oct; 112(10):1067-1068. PubMed ID: 32602898
    [No Abstract]   [Full Text] [Related]  

  • 7. Evolving detection and treatment methods change approaches to prostate cancer: US Preventive Services Task Force draft recommendations now align more closely with others.
    Printz C
    Cancer; 2018 Jan; 124(1):11-12. PubMed ID: 29251768
    [No Abstract]   [Full Text] [Related]  

  • 8. New US Preventive Service Task Force recommendations for prostate cancer screening: a needed update, but not enough.
    Wroclawski ML
    Einstein (Sao Paulo); 2017; 15(3):7-10. PubMed ID: 29091165
    [No Abstract]   [Full Text] [Related]  

  • 9. The current state of prostate-specific antigen testing.
    Lewis R; Hornberger B
    JAAPA; 2016 Sep; 29(9):51-3. PubMed ID: 27575906
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Re: Turini et al.: The State of Prescreening Discussions About Prostate-specific Antigen Testing Following Implementation of the 2012 United States Preventive Services Task Force Statement (Urology 2017;104:122-130).
    de Riese W; Verlage K; Grand R; de Riese CS; Cammack JT
    Urology; 2018 Apr; 114():246. PubMed ID: 28554516
    [No Abstract]   [Full Text] [Related]  

  • 11. US Preventive Services Task Force prostate-specific antigen screening guidelines result in higher Gleason score diagnoses.
    Gejerman G; Ciccone P; Goldstein M; Lanteri V; Schlecker B; Sanzone J; Esposito M; Rome S; Ciccone M; Margolis E; Simon R; Guo Y; Pentakota SR; Sadeghi-Nejad H
    Investig Clin Urol; 2017 Nov; 58(6):423-428. PubMed ID: 29124241
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Testing and referral patterns in the years surrounding the US Preventive Services Task Force recommendation against prostate-specific antigen screening.
    Hutchinson R; Akhtar A; Haridas J; Bhat D; Roehrborn C; Lotan Y
    Cancer; 2016 Dec; 122(24):3785-3793. PubMed ID: 27658175
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prostate Needle Biopsy Outcomes in the Era of the U.S. Preventive Services Task Force Recommendation against Prostate Specific Antigen Based Screening.
    Banerji JS; Wolff EM; Massman JD; Odem-Davis K; Porter CR; Corman JM
    J Urol; 2016 Jan; 195(1):66-73. PubMed ID: 26254722
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Grading the new US Preventive Services Task Force prostate cancer screening recommendation.
    Volk RJ; Wolf AM
    JAMA; 2011 Dec; 306(24):2715-6. PubMed ID: 22203540
    [No Abstract]   [Full Text] [Related]  

  • 15. Stratifying risk--the U.S. Preventive Services Task Force and prostate-cancer screening.
    Schröder FH
    N Engl J Med; 2011 Nov; 365(21):1953-5. PubMed ID: 22029756
    [No Abstract]   [Full Text] [Related]  

  • 16. Impact of the United States Preventive Services Task Force 'D' recommendation on prostate cancer screening and staging.
    Eapen RS; Herlemann A; Washington SL; Cooperberg MR
    Curr Opin Urol; 2017 May; 27(3):205-209. PubMed ID: 28221220
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prostate-cancer screening--what the U.S. Preventive Services Task Force left out.
    Brett AS; Ablin RJ
    N Engl J Med; 2011 Nov; 365(21):1949-51. PubMed ID: 22029759
    [No Abstract]   [Full Text] [Related]  

  • 18. The impact of the United States Preventive Services Task Force (USPTSTF) recommendations against prostate-specific antigen (PSA) testing on PSA testing in Australia.
    Zargar H; van den Bergh R; Moon D; Lawrentschuk N; Costello A; Murphy D
    BJU Int; 2017 Jan; 119(1):110-115. PubMed ID: 27454454
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of the 2008 US Preventive Services Task Force recommendation to discontinue prostate cancer screening among male Medicare beneficiaries.
    Ross JS; Wang R; Long JB; Gross CP; Ma X
    Arch Intern Med; 2012 Nov; 172(20):1601-3. PubMed ID: 22987029
    [No Abstract]   [Full Text] [Related]  

  • 20. Decrease in Prostate Cancer Testing Following the US Preventive Services Task Force (USPSTF) Recommendations.
    Li J; Berkowitz Z; Hall IJ
    J Am Board Fam Med; 2015; 28(4):491-3. PubMed ID: 26152440
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.